Skip to main content
Ocugen, Inc. logo

Ocugen, Inc. — Investor Relations & Filings

Ticker · OCGN ISIN · US43358V1098 LEI · 549300JVNUI9CXWJLR09 US Manufacturing
Open in API
Filings indexed 849 across all filing types
Latest filing 2015-04-28 Remuneration Information
Country US United States of America
Listing US OCGN

About Ocugen, Inc.

https://ocugen.com/

Ocugen, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel gene therapies, cell therapies, and vaccines. The company's primary mission is to develop treatments for blindness diseases, leveraging its first-in-class modifier gene therapy platform. This platform represents a potential paradigm shift in treating inherited retinal diseases by aiming to address multiple genetic mutations with a single product. In addition to its focus on ocular health, Ocugen is also advancing a pipeline that includes vaccines for infectious diseases. The company is dedicated to addressing significant unmet medical needs and providing innovative therapeutic options for patients with debilitating conditions.

Recent filings

Filing Released Lang Actions
DEFA14A
Remuneration Information Classification · 95% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or additional materials related to a shareholder meeting. It includes information about the upcoming Annual Meeting, voting instructions, and proposals to be voted on, such as election of directors and approval of executive compensation. It is not the actual proxy statement itself but additional materials related to it. The document is not a full annual report, earnings release, or other financial report. It fits the category of Remuneration Information (DEF 14A) because it includes advisory votes on executive compensation and is filed as a DEFA14A form, which is specifically for remuneration and proxy materials.
2015-04-28 English
DEF 14A
Proxy Solicitation & Information Statement
2015-04-28 English
10-K
Annual Report FY 2014
2015-03-27 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The content describes the appointment of an interim Chief Financial Officer and details about a consulting agreement and warrant issuance. This is an announcement of a change in senior management. There are no financial statements or detailed financial performance data, so it is not an Annual Report or Interim Report. The document fits the category of Board/Management Information (MANG) as it announces management changes.
2015-03-16 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated March 2, 2015, reporting the resignation of an executive officer, specifically the Chief Financial Officer, Kevin McArdle. The content focuses on management changes, including resignation and plans for replacement. There are no financial statements or detailed financial data presented. The document is not an annual or quarterly report, nor is it an earnings release or audit report. It clearly fits the category of announcements related to changes in the company's board or senior management. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is 3081 characters, which is consistent with a typical 8-K management change filing rather than a full report.
2015-03-06 English
FORM 4 SUBMISSION
Director's Dealing
2015-02-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.